DUBAI, UAE, Oct. 18, 2024 /PRNewswire/ -- During GITEX GLOBAL 2024, Huawei signed a strategic cooperation agreement with Alinma Bank to accelerate the digital transformation in the financial industry.
Alinma Bank, a Saudi Arabian epicenter for dynamic, innovative, Shariah-compliant banking and financial services, has partnered with Huawei for several years. This new agreement marks a major step forward in their cooperation.
Jason Cao, CEO of Digital Finance BU, Huawei, emphasized the robust relationship between Huawei and Alinma Bank. He said, "Alinma Bank is a leading bank in the Middle East with a great vision. Huawei looks forward to expanding the partnership to support Alinma Bank's digital transformation success with our technology, solutions and global experiences."
Trevor Liu, CEO of Huawei Saudi Rep. Office, underlined, "Huawei Saudi Office will go all out to support Alinma Bank with our best expertise in the team. We expect to gain a deeper understanding of the needs of Alinma Bank and provide the most suitable solutions and services to accelerate the digital transformation of Alinma Bank."
Yasser Aloufi, Chief Information Officer of Alinma Bank, said, "Huawei is our strategic partner. Since the cooperation started several years ago in IT infrastructure, we have been very satisfied with Huawei's performance. We are looking forward to deepening the cooperation with Huawei, which could expand from infrastructure to cloud solutions, and further evolve into a digital transformation partnership."
Huawei leverages leading innovative technologies and draws on its extensive expertise to help customers succeed through open collaboration with financial institutions and ecosystem partners, always looking for new ways to create value for our customers. By the end of September 2024, Huawei had served over 3,700 financial customers in more than 80 countries and regions, including 53 of the world's top 100 banks. Huawei had also established strategic partnerships with more than 80 large banks, insurers, and securities companies across the globe, becoming their trusted partner in digital transformation.
For more details, please visit: https://e.huawei.com/en/industries/finance
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Huawei and Alinma Bank Establish Strategic Partnership at GITEX GLOBAL 2024
SAN FRANCISCO, Oct. 18, 2024 /PRNewswire/ -- Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These development programs offer new potentials for the future treatment of Nontuberculous Mycobacterial (NTM) pulmonary diseases and Pseudomonas aeruginosa (PsA) pulmonary infections.
MRX-5, a novel benzoxaborole antibiotic, is developed for the treatment of rare chronic pulmonary disease caused by NTM infection. MRX-5 exhibits excellent antibacterial activity against common NTM pathogens and demonstrates good safety in animal trials.MABC affects approximately 12,000 to 20,000 patients in the US and requires treatment durations exceeding 12 months. MRX-5 holds promise for addressing NTM infections.
MRX-8, a novel antibiotic in the polymyxin class, is designed to treat severe infections caused by multidrug-resistant Gram-negative bacteria. Traditional polymyxins are limited in clinical use due to high risks of nephrotoxicity and neurotoxicity. MRX-8, with its novel chemical structure, maintains or improves therapeutic efficacy while significantly reducing these risks.
The company also aims to explore the clinical and commercial potential of developing an inhaled formulation targeting chronic lung infections. In mouse models of PsA lung infections, nebulized MRX-8 demonstrated significant reduction in bacterial load in lung tissues, indicating strong bactericidal activity.
At the forum, Dr. Regis Vilchez focused on presenting the development progress and future plans for MRX-5 and MRX-8, while analyzing the significant market demand for treatments targeting NTM lung disease and chronic PsA pulmonary infections. These two pipeline products are expected to fill gaps in the treatment of NTM lung disease and chronic PsA pulmonary infections, offering patients safer and more effective new treatment options.
MicuRx Pharmaceuticals remains committed to discovering, developing, and commercializing innovative medicines to meet unmet clinical needs, providing patients with differentiated therapeutic solutions. The company will continue to actively advance the development of MRX-5 and MRX-8, aiming to bring these innovative drugs to market as soon as possible, bringing hope to patients worldwide.
For more information, please contact:
MicuRx Pharmaceuticals, Inc.
Website: www.micurx.com
About MicuRx Pharmaceuticals
MicuRx Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibiotics for the treatment of multidrug-resistant infections. With a mission to address significant unmet medical needs, MicuRx is advancing a portfolio of drug candidates targeting difficult-to-treat infections.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum
